Is Psilocybin Therapy Legal in the UK?

No. Psilocybin therapy is not legal in the UK outside an approved clinical trial. Psilocybin is a Class A drug and sits in Schedule 1 of the drug regulations, which means no doctor can prescribe it, no clinic can offer it and nobody can sell it as a session, however the website words it.

That is the whole legal answer, and it has been for years. What has changed is the research around it. A London-founded company has taken psilocybin through late-stage trials and into the American approval process, the UK government has agreed in principle to make research easier, and the gap between "being studied" and "being available" has never been reported more loosely. This post is about that gap: what psilocybin therapy in the UK means in law today, and what would have to happen before it meant anything else.

Is psilocybin therapy available in the UK at all?

Only as research. The one lawful setting is a clinical trial: a named study at a university or hospital, approved by the medicines regulator and an ethics committee, run under a Home Office licence that covers that institution and that protocol. A participant in a trial is part of an experiment. They are not a patient receiving an approved treatment, and the trial gives nobody outside it any legal cover.

Psilocybin clinical trials in the UK are also small and finite. The research team picks its participants against the protocol, the doses are logged to the milligram, and when the study ends, so does the access: no follow-on supply, no repeat prescription, nothing to take home. Is psilocybin therapy legal in that narrow sense? Yes, for the people inside each study, for as long as it runs.

Everything else is the ordinary criminal law. The gov.uk penalties table puts Class A possession at up to seven years and supply at up to life. A "guided session" counts as supply in law, whether money changes hands or not. We set out the full position in is psilocybin legal in the UK, and none of it softens because the word therapy is attached.

Why can't a UK doctor prescribe psilocybin?

Because of the list it is on. UK drug law runs two systems side by side. The class, under the Misuse of Drugs Act 1971, sets the penalties. The schedule, under the Misuse of Drugs Regulations 2001, decides who may lawfully hold a drug and why. Psilocybin is in Schedule 1, the tier for drugs the law treats as having no recognised medical use. Morphine and cocaine sit in Schedule 2 and can be prescribed. Psilocybin cannot, by any doctor, for any condition, privately or on the NHS.

Getting it out of Schedule 1 is not something a minister does on a hunch. The Home Office has said its order of events runs one way: first a psilocybin medicine gets a marketing authorisation from the MHRA, the UK medicines regulator, and only then does the scheduling question come back to the Advisory Council on the Misuse of Drugs. Licence first, list second. Campaigners call that a loop, since the trials needed for a licence are slower and dearer while the drug sits in Schedule 1. We follow that argument in detail in the fight to reschedule psilocybin.

The government's one concession so far is aimed at the lab. In its response to the ACMD on 16 July 2025, it accepted in principle that universities, hospitals and approved trials should be exempt from the separate Home Office licence, to be tested through a pilot. That would make studies cheaper and quicker to start. It would not move psilocybin off Schedule 1, and it would not let anyone prescribe it.

What about clinics and retreats offering psilocybin therapy in the UK?

Any UK provider offering psilocybin sessions is operating outside the law, and the legal risk is not small. Supplying a Class A drug carries a maximum of life imprisonment, and the person who takes the dose is committing possession at the same time. A consent form, a calm room and a qualified practitioner change none of that.

The confusion has a source. Several legal UK clinics advertise "psychedelic-assisted therapy", and the drug they use is ketamine. Ketamine is controlled too, but it sits in Schedule 2, so a doctor can prescribe it off-label. Psilocybin has no such route. If a UK service is lawful, it is not giving you psilocybin, and if it is giving you psilocybin, it is not lawful.

Travelling abroad does not move the line either. A supervised session that is legal where it happens stays legal there, and UK law still applies the moment you are home, as we explain in the psilocybin post linked above. Nothing here should be read as a pointer to any service anywhere.

What would a legal psilocybin therapy route actually take?

Three separate decisions, made by three separate bodies, in roughly this order.

First, a licence from the MHRA. That means a company applying with full trial data and the regulator deciding the product is safe and effective enough to authorise. The nearest candidate is COMP360, a synthetic psilocybin developed by Compass Pathways, which was founded in London. The company has reported that two late-stage trials in treatment-resistant depression met their primary endpoint, the second in February 2026, and it has begun filing with the US regulator, the FDA, with a US launch in 2027 the earliest it has named. No application to the MHRA has been announced. Even in America, approval would still need the drug moved out of its own Schedule I before anyone could prescribe it.

Second, a scheduling change in the UK. On the Home Office's own logic, a licensed product reopens the question. Precedent exists: Sativex, the cannabis-based spray in our look at medical cannabis in the UK, moved schedule in 2013 after it was licensed. But a precedent is not a promise, and the 2018 cannabis change showed how political this step can be.

Third, access. A licensed, rescheduled medicine is still not on the NHS until NICE recommends it, and medical cannabis is the warning there: legal on prescription since November 2018, and still rarely prescribed through the NHS.

Other countries have taken shortcuts. Australia has let specially authorised psychiatrists prescribe psilocybin for treatment-resistant depression since July 2023, a policy choice made before any product was registered there. Nothing like it is in motion in the UK.

So where does that leave psilocybin therapy in the UK?

In the lab, and nowhere else. The research is moving faster than it was, the regulator in Washington will decide on COMP360 before London is even asked, and the Home Office has kept its formal position that psilocybin has no recognised medical use. A trial result is news. It changes nothing for someone outside a trial this year.

Adult access, the thing this site is waiting for, is a separate and longer argument than medical approval, and as with cannabis, nobody honest can give you a date.

High in Hackney is a waitlist for the day UK law changes for adults, for cannabis and for psilocybin. Nothing is sold here and nothing can be until Parliament acts, but the people on the list hear first when it does. Join the waitlist